This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT)
by Zacks Equity Research
ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%
by Zacks Equity Research
AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.
ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study
by Zacks Equity Research
ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are unfit or frail.
Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study
by Zacks Equity Research
Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the treatment of pancreatic cancer.
Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30%
by Zacks Equity Research
Novavax (NVAX) is set to receive $350M from the Canadian government for forfeited Covid-19 vaccine doses per an amendment to the original purchase agreement between the parties. The stock rises 30%.
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 7.50% and 5.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals (XENE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Xenon Pharmaceuticals (XENE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate ADC Therapeutics SA (ADCT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seres Therapeutics (MCRB) Moves 10.9% Higher: Will This Strength Last?
by Zacks Equity Research
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
by Zacks Equity Research
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
by Zacks Equity Research
Data from late-stage label expansion studies show that AstraZeneca's (AZN) cancer drugs are effective for treating non-small cell lung cancer indications.
BioMarin (BMRN) Provides FDA Filing Update for Gene Therapies
by Zacks Equity Research
The FDA accepts BioMarin's (BMRN) label-expansion filing for Voxzogo to treat children under five years with achondroplasia. The agency extends the review period for Roctavian BLA.
Down -36.18% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
by Zacks Equity Research
ADC Therapeutics SA (ADCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 38.78% and 7.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Molina (MOH) to Post Q4 Earnings: What You Should Expect
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.
Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
by Zacks Equity Research
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
Amarin Corporation (AMRN) Down 13% in One Week: Here's Why
by Zacks Equity Research
Shares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors.
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for ADC Therapeutics SA (ADCT) points to a 174.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?
by Zacks Equity Research
ADC Therapeutics SA (ADCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Land on 4 Winning Stocks Using the Overlooked Rising P/E Trick
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap four stocks, namely Eastside Distilling (EAST), AMC Entertainment (AMC), CuriosityStream (CURI) and ADC Therapeutics (ADCT).
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of -27.45% and 37.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of -17.50% and 5.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Therapeutics (ARCT) Surges 18.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Arcturus Therapeutics (ARCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.